GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Mohanram G-Score

HighTide Therapeutics (HKSE:02511) Mohanram G-Score : N/A (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Mohanram G-Score?

HighTide Therapeutics does not have enough data to calculate Mohanram G-Score.


HighTide Therapeutics Mohanram G-Score Historical Data

The historical data trend for HighTide Therapeutics's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Mohanram G-Score Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Mohanram G-Score
N/A N/A N/A

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Mohanram G-Score N/A N/A N/A N/A N/A

Competitive Comparison of HighTide Therapeutics's Mohanram G-Score

For the Biotechnology subindustry, HighTide Therapeutics's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics's Mohanram G-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Mohanram G-Score falls into.



HighTide Therapeutics Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

HighTide Therapeutics  (HKSE:02511) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


HighTide Therapeutics Mohanram G-Score Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Mohanram G-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics (HKSE:02511) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Executives
Ma Lixiong 2101 Beneficial owner
Liu Liping 2101 Beneficial owner
Li Li 2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao 2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc. 2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p 2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited 2101 Beneficial owner
Hepalink (hong Kong) Limited 2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited 2101 Beneficial owner
Lai Hoi Man 2201 Interest of corporation controlled by you
Hongtu Capital Limited 2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines